Group 1 - The core point of the article is that Furuida plans to divest its 100% stake in Shandong Lushang Yinzou Commercial Management Co., Ltd. to focus on its main business and improve operational quality, with the transaction valued at 88.4028 million yuan [1] - After the transaction, Furuida will no longer hold any equity in Yinzou Commercial Management [1] - As of the first half of 2025, Furuida's revenue composition is as follows: cosmetics 61.13%, property leasing 16.37%, pharmaceuticals 11.57%, additives 9.98%, and other businesses 0.95% [1] Group 2 - Furuida's market capitalization is currently 7.9 billion yuan [2]

本资产评估报告依据中国资产评估准则编制 鲁商福瑞达医药股份有限公司 拟转让股权所涉及的 山东鲁商银座商业管理有限公司 股东全部权益价值 产评估报 鹏信资评报字[2025]第 S032 号 评估基准日:2024年12月31日 资产评估报告日:2025年03月18日 en Xin 深圳市鹏信资产评估土地房地产估价有限公司 SHENZHEN PENGXIN APPRAISAL LIMITED 中国广东省深圳市福田区福中路29号(彩田路口)福景大厦中座十四楼 Floor 14, Middle Block, Fujing Building, 29 Fuzhong Road, Futian District,Shenzhen, China 电话(Tel):+86755-8240 6288 直线(Dir):+86755-8240 3555 http://www.pengxin.com 传真(Fax):+86755-8242 0222 邮政编码(Postcode):518026 Email: px@pengxin.com 中国资产评估协会 备案回执生成日期:2025年03月19日 ICP备案号京ICP备2020034749号 ...

证券代码：600223 证券简称：福瑞达 编号：临 2025-030 鲁商福瑞达医药股份有限公司 关于转让全资子公司山东鲁商银座商业管理有限公司 100%股权暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 为聚焦主业发展，持续提升公司运行质量，鲁商福瑞达医药股份有限公司 （以下简称"公司"）拟将持有的山东鲁商银座商业管理有限公司（以下简称"银 座商管"）100%股权转让给鲁商福瑞达健康投资有限公司，交易价款依据评估值 确定为8,840.28万元。本次交易完成后，公司将不再持有银座商管的股权。 本次交易方鲁商福瑞达健康投资有限公司与公司为同受山东省商业集团 有限公司控制的公司，故本次交易构成关联交易。 本次交易未构成重大资产重组。 公司不存在为银座商管提供担保、委托理财，以及该公司占用上市公司资 金等方面的情况。 至本次关联交易为止，过去12个月内公司与同一关联人或与不同关联人之 间交易类别相同的关联交易未达到公司最近一期经审计净资产绝对值5%以上（不 含已履行相关程序的关联交易），本次关联 ...

法律意见书 国浩律师（济南）事务所 关于鲁商福瑞达医药股份有限公司 2025 年第一次临时股东会 之 济南市龙奥西路 1 号银丰财富广场 C 座 19、20、25 层 邮编：250014 19th-20th、25thFloor,BlockC,YinfengFortunePlaza,No.1Long'aoWestRoad,Jinan 电话/Tel:+8653186112118 传真/Fax:+8653186110945 网址/Website:http://www.grandall.com.cn 二〇二五年十月 国浩律师（济南）事务所（以下简称"本所"）接受鲁商福瑞达医药股份有 限公司（以下简称"福瑞达"或"公司"）的委托，指派本所律师林泽若明、张 灵君（以下简称"本所律师"）出席福瑞达 2025 年第一次临时股东会（以下简 称"本次股东会"），并出具本法律意见书。 为出具本法律意见书，本所律师出席了本次股东会，并依据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简 称"《证券法》"）、《律师事务所从事证券法律业务管理办法》和《律师事务 所证券法律业务执业规则》等法律法规及规 ...

证券代码：600223 证券简称：福瑞达 公告编号：2025-029 鲁商福瑞达医药股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 （一）股东会召开的时间：2025 年 10 月 10 日 （二）股东会召开的地点：山东省济南市高新区新泺大街 888 号公司会议室 （三）出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 604 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 577,748,396 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份 | | | 总数的比例（%） | 56.8331 | （四）表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本次股东会由公司董事会召集，会议由贾庆文先生主持。本次股东会采取现场投 票和网络投票相结合的方式进行表决。本次股东会的召集、召开及表决方 ...

独立董事：宿玉海、朱德胜 2025 年 10 月 11 日 鲁商福瑞达医药股份有限公司 第十二届董事会独立董事专门会议决议 鲁商福瑞达医药股份有限公司（以下简称"公司"）第十二届董事会独立董事专 门会议于 2025 年 9 月 30 日发出通知，并于 2025 年 10 月 9 日在公司会议室召开。 经过半数独立董事共同推举，本次会议由独立董事宿玉海召集和主持，本次会议应 参会独立董事 2 名，实际参加表决的独立董事 2 名，本次会议的召集、召开符合《中 华人民共和国公司法》《上市公司独立董事管理办法》《公司章程》《独立董事工作制 度》等有关规定，会议合法有效。 经参会独立董事审议，一致通过《关于转让全资子公司山东鲁商银座商业管理 有限公司 100%股权暨关联交易的议案》，独立董事认为：本次关联交易遵循了客观、 公正的原则，估值合理、价格公允，符合《公司法》《证券法》《上海证券交易所股 票上市规则》等法律法规和《公司章程》的有关规定，本次转让山东鲁商银座商业 管理有限公司 100%股权，有利于公司进一步优化资源配置，聚焦主业，符合公司战 略规划和发展需要，不存在损害公司及其他股东特别是中、小股东利益的情形。同 ...

Core Insights - The cosmetics sector experienced a rise of 1.51% on October 10, with Shuiyang Co. leading the gains [1] - The Shanghai Composite Index closed at 3897.03, down 0.94%, while the Shenzhen Component Index closed at 13355.42, down 2.7% [1] Company Performance - Shuiyang Co. (300740) closed at 23.93, up 8.72%, with a trading volume of 397,000 shares and a transaction value of 931 million yuan [1] - Jiahen Jiahua (300955) closed at 37.76, up 7.95%, with a trading volume of 119,800 shares and a transaction value of 438 million yuan [1] - Lafang Jiahua (603630) closed at 23.80, up 3.30%, with a trading volume of 73,600 shares and a transaction value of 17.5 million yuan [1] - Other notable performers include Bawi Co. (920123) up 2.45%, Shanghai Jahwa (600315) up 1.91%, and Jingsheng New Materials (300849) up 1.40% [1] Fund Flow Analysis - The cosmetics sector saw a net inflow of 96.14 million yuan from institutional investors, while retail investors experienced a net outflow of 98.20 million yuan [1] - Shuiyang Co. had a net inflow of 43.09 million yuan from institutional investors, but a net outflow of 33.48 million yuan from retail investors [2] - Jiahen Jiahua recorded a net inflow of 33.03 million yuan from institutional investors, with a significant net outflow of 67.04 million yuan from retail investors [2]

Investment Rating - The report maintains a "Recommend" rating for the company with a target price of 10.11 yuan [2][9]. Core Views - The company is experiencing a phase of performance pressure, with a 7.05% year-on-year decline in revenue and a 15.16% drop in net profit for the first half of 2025. The revenue for 25H1 was 1.79 billion yuan, and the net profit was 108 million yuan [2][9]. - The company is undergoing strategic adjustments, particularly in its product lines, with expectations for performance recovery as new products are launched and adjustments take effect [9]. Financial Performance Summary - **2025 Half-Year Performance**: Revenue was 1.79 billion yuan (-7.05% YoY), and net profit was 108 million yuan (-15.16% YoY). The gross margin was 52.3% (+0.5pp YoY), and the net margin was 7.5% (-0.6pp YoY) [2]. - **2025 Q2 Performance**: Revenue was 913 million yuan (-11.7% YoY), and net profit was 57 million yuan (-16.1% YoY). The gross margin was 53.4% (+0.6pp YoY), and the net margin was 7.8% (-0.2pp YoY) [2]. - **Future Financial Projections**: Expected revenues for 2024A, 2025E, 2026E, and 2027E are 3.983 billion, 3.798 billion, 4.189 billion, and 4.598 billion yuan respectively, with corresponding net profits of 244 million, 248 million, 294 million, and 350 million yuan [5][10]. Business Segment Performance - **Cosmetics Segment**: Revenue was 1.094 billion yuan (-7.73% YoY). The "Yilian" brand showed strong growth with a 23.78% increase in revenue to 554 million yuan, driven by successful marketing and product upgrades [9]. - **Raw Materials Segment**: Revenue was 179 million yuan (+4.15% YoY), with a notable increase in high-value products, particularly in hyaluronic acid (HA) sales, which grew by 287.3% YoY [9]. R&D and Innovation - The company continues to invest in R&D, with expenses increasing by 20.60% YoY to 79 million yuan in the first half of 2025. New product launches, including the "transdermal collagen" technology, are expected to drive future growth [9].

Core Insights - The Yilian brand, under Furuida Biological Co., has achieved a brand value assessment exceeding 12 billion yuan, establishing itself as a benchmark in the domestic fragrance and cosmetics industry [2][10] - The brand value assessment utilized a model that integrates international best practices with Chinese market characteristics, focusing on three dimensions: brand benchmark revenue, brand strength index, and brand development index [4] - The assessment involved a comprehensive survey of 30 international brands, 15 domestic listed brands, 115 traditional domestic brands, 30 emerging domestic brands, and 10 domestic time-honored brands [4] Brand Performance - Yilian excelled in key indicators such as revenue scale, research and development capabilities, brand cultural strength, and ESG performance, leading to its brand value recognition of 12 billion yuan [4][10] - The brand's principal, Jiang Liangyan, emphasized the importance of balancing short-term sales growth with long-term brand value, advocating for a transition from "traffic brands" to "value brands" [6] Assessment Framework - The brand value assessment framework serves as a "value declaration," encouraging brands to achieve a harmonious ecosystem beyond just sales and visibility [8] - The framework aims to inspire companies to become respected by consumers and the industry, thereby enhancing the visibility and transmission of good brand values [8] Strategic Direction - Yilian's commitment to a "technology + culture" development philosophy focuses on the hyaluronic acid moisturizing and repair sector, reflecting its strategic achievements in global competition [10] - The brand aims to continue driving innovation and leading the Chinese fragrance and cosmetics industry towards higher value dimensions [10]

每经AI快讯，有投资者在投资者互动平台提问：贵司两款三类医疗器械研发进度是否顺利，明年能否 按期取证？ 福瑞达（600223.SH）9月30日在投资者互动平台表示，公司两款三类医疗器械按研发计划推进中，HA 水光针（Ⅲ类）完成所有中心的临床试验启动，且已完成所有中心的病例入组；胶原蛋白冻干纤维（Ⅲ 类）正在开展注册检验、生物学评价，进度符合研发计划，研发与临床团队全力推进中。 （文章来源：每日经济新闻） ...